BJDX

Company Overview — What Does Bluejay Diagnostics, Inc. Do?

Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts. Bluejay Diagnostics, Inc. (BJDX) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Indranil Dey and employs approximately 9 people. With a market capitalization of $2M, BJDX is one of the notable companies in the Healthcare sector.

Bluejay Diagnostics, Inc. (BJDX) Stock Rating — Reduce (April 2026)

As of April 2026, Bluejay Diagnostics, Inc. receives a Reduce rating with a composite score of 29.0/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.BJDX ranks #3,426 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Bluejay Diagnostics, Inc. ranks #528 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

BJDX Stock Price and 52-Week Range

Bluejay Diagnostics, Inc. (BJDX) currently trades at $1.78. The stock lost $0.03 (1.7%) in the most recent trading session. The 52-week high for BJDX is $10.20, which means the stock is currently trading -82.5% from its annual peak. The 52-week low is $0.63, putting the stock 183.8% above its annual trough. Recent trading volume was 37K shares, suggesting relatively thin trading activity.

Is BJDX Overvalued or Undervalued? — Valuation Analysis

Bluejay Diagnostics, Inc. (BJDX) carries a value factor score of 8/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.35x, versus the sector average of 2.75x.

At current multiples, Bluejay Diagnostics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Bluejay Diagnostics, Inc. Profitability — ROE, Margins, and Quality Score

Bluejay Diagnostics, Inc. (BJDX) earns a quality factor score of 17/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -115.5%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -96.9% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

BJDX Debt, Balance Sheet, and Financial Health

Bluejay Diagnostics, Inc. has a debt-to-equity ratio of 19.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 4.88x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $3M.

BJDX has a beta of -0.11, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Bluejay Diagnostics, Inc. is 34/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Bluejay Diagnostics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Bluejay Diagnostics, Inc. reported revenue of $0 and earnings per share (EPS) of $-15.25. Net income for the quarter was $-7M. Operating income came in at $-7M.

In FY 2025, Bluejay Diagnostics, Inc. reported revenue of $0 and earnings per share (EPS) of $-15.25. Net income for the quarter was $-7M. Operating income came in at $-7M.

In Q3 2025, Bluejay Diagnostics, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.01. Net income for the quarter was $-2M. Operating income came in at $-2M.

In Q2 2025, Bluejay Diagnostics, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.41. Net income for the quarter was $-2M. Operating income came in at $-2M.

Over the past 8 quarters, Bluejay Diagnostics, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing BJDX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

BJDX Dividend Yield and Income Analysis

Bluejay Diagnostics, Inc. (BJDX) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

BJDX Momentum and Technical Analysis Profile

Bluejay Diagnostics, Inc. (BJDX) has a momentum factor score of 40/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 69/100 reflects moderate short selling activity.

BJDX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Bluejay Diagnostics, Inc. (BJDX) ranks #528 out of 838 stocks based on the Blank Capital composite score. This places BJDX in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing BJDX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full BJDX vs S&P 500 (SPY) comparison to assess how Bluejay Diagnostics, Inc. stacks up against the broader market across all factor dimensions.

BJDX Next Earnings Date

No upcoming earnings date has been announced for Bluejay Diagnostics, Inc. (BJDX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy BJDX? — Investment Thesis Summary

The quantitative profile for Bluejay Diagnostics, Inc. suggests caution. The quality score of 17/100 flags below-average profitability. The value score of 8/100 indicates premium valuation. High volatility (stability score 34/100) increases portfolio risk.

In summary, Bluejay Diagnostics, Inc. (BJDX) earns a Reduce rating with a composite score of 29.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on BJDX stock.

Related Resources for BJDX Investors

Explore more research and tools: BJDX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare BJDX head-to-head with peers: BJDX vs AZN, BJDX vs SLGL, BJDX vs VMD.